Rotational Support of Giant Clumps in High-z Disc Galaxies

We address the internal support against total free-fall collapse of the giant clumps that form by violent gravitational instability in high-z disc galaxies. Guidance is provided by an analytic model, where the proto-clumps are cut from a rotating disc and collapse to equilibrium while preserving angular momentum. This model predicts prograde clump rotation. This is confirmed in hydro-AMR zoom-in simulations of galaxies in a cosmological context. In most high-z clumps, the centrifugal force dominates the support, R=Vrot^2/Vcirc^2 > 0.5, where Vrot is the rotation velocity and Vcirc is the circular velocity. The clump spin indeed tends to be in the sense of the global disc angular momentum, but substantial tilts are frequent. Most clumps are in Jeans equilibrium, with the rest of the support provided by turbulence. Simulations of isolated gas-rich discs that resolve the clump substructure reveal that the cosmological simulations may overestimate R by ~30%, but the dominance of rotational support at high-z is not a resolution artifact. In turn, isolated gas-poor disc simulations produce at z=0 smaller gaseous non-rotating transient clouds, indicating that the difference in rotational support is associated with the fraction of cold baryons in the disc. In our current cosmological simulations, the clump rotation velocity is typically Vrot~100 km/s, but when beam smearing of \geq 0.1 arcsec is imposed, the rotation signal is reduced to a small gradient of \leq 30 km/s/kpc across the clump. The velocity dispersion in the simulated clumps is comparable to the disc dispersion so it is expected to leave only a marginal signal. Retrograde minor-merging galaxies could lead to massive clumps that do not show rotation.Testable predictions of the scenario as simulated are that the mean stellar age of the clumps, and the stellar fraction, are declining linearly with distance from the disc center.Comment: accepted at MNRAS, 34 pages, 25 figures, 5 tables, movies and high-resolution version can be found at http://www.phys.huji.ac.il/~ceverino/Site/Welcome.htm

Risk and safety requirements for diagnostic and therapeutic procedures in allergology : World Allergy Organization Statement

Peer reviewe

Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection

Abstract Background Chronic active antibody-mediated rejection (c-aABMR) is an important cause of allograft failure and graft loss in long-term kidney transplants. Methods To determine the efficacy and safety of combined therapy with rituximab, plasma exchange (PE) and intravenous immunoglobulins (IVIG), a cohort of patients with transplant glomerulopathy (TG) that met criteria of active cABMR, according to BANFF’17 classification, was identified. Results We identified 62 patients with active c-aABMR and TG (cg ≥ 1). Twenty-three patients were treated with the combination therapy and, 39 patients did not receive treatment and were considered the control group. There were no significant differences in the graft survival between the two groups. The number of graft losses at 12 and 24 months and the decline of eGFR were not different and independent of the treatment. A decrease of eGFR≥13 ml/min between 6 months before and c-aABMR diagnosis, was an independent risk factor for graft loss at 24 months (OR = 5; P = 0.01). Infections that required hospitalization during the first year after c-aABMR diagnosis were significantly more frequent in treated patients (OR = 4.22; P = 0.013), with a ratio infection/patient-year of 0.65 and 0.20 respectively. Conclusions Treatment with rituximab, PE, and IVIG in kidney transplants with c-aABMR did not improve graft survival and was associated with a significant increase in severe infectious complications. Trial registration Agencia Española de Medicametos y Productos Sanitarios (AEMPS): 14566/RG 24161. Study code: UTR-INM-2017-01

A WAO - ARIA - GA²LEN consensus document on molecular-based allergy diagnostics.

Molecular-based allergy (MA) diagnostics is an approach used to map the allergen sensitization of a patient at a molecular level, using purified natural or recombinant allergenic molecules (allergen components) instead of allergen extracts. Since its introduction, MA diagnostics has increasingly entered routine care, with currently more than 130 allergenic molecules commercially available for in vitro specific IgE (sIgE) testing.MA diagnostics allows for an increased accuracy in allergy diagnosis and prognosis and plays an important role in three key aspects of allergy diagnosis: (1) resolving genuine versus cross-reactive sensitization in poly-sensitized patients, thereby improving the understanding of triggering allergens; (2) assessing, in selected cases, the risk of severe, systemic versus mild, local reactions in food allergy, thereby reducing unnecessary anxiety for the patient and the need for food challenge testing; and (3) identifying patients and triggering allergens for specific immunotherapy (SIT).Singleplex and multiplex measurement platforms are available for MA diagnostics. The Immuno-Solid phase Allergen Chip (ISAC) is the most comprehensive platform currently available, which involves a biochip technology to measure sIgE antibodies against more than one hundred allergenic molecules in a single assay. As the field of MA diagnostics advances, future work needs to focus on large-scale, population-based studies involving practical applications, elucidation and expansion of additional allergenic molecules, and support for appropriate test interpretation. With the rapidly expanding evidence-base for MA diagnosis, there is a need for allergists to keep abreast of the latest information. The aim of this consensus document is to provide a practical guide for the indications, determination, and interpretation of MA diagnostics for clinicians trained in allergology

Erratum to: Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement

Unfortunately, the original version of this article [1] contained an error. The spelling of author name Vera van Kempen was incorrect. The correct spelling can be found below